FDA Requests More Information From ARCA Biopharma
The Food and Drug Administration requested more information and additional studies from ARCA Biopharma Inc. (Nasdaq: ABIO) for its heart failure medication Gencaro. Shares of the biopharmaceutical plummeted $4.16 to close at $5.13.
